Suspended PHASE2 INTERVENTIONAL 2-arm NCT01235273

Treatment of the lOw IGF-1 Syndrome aSsociated With Chronic Heart fAilure: A Randomized, Placebo-Controlled, Double-Blind Study. (TOSCA2)

Phase 2 Study of Growth Hormone Administration in Patients With Chronic Heart Failure and Low IGF-1 Levels

Sponsor: Federico II University

Updated 5 times since 2017 Last updated: Feb 18, 2014 Started: Jan 31, 2011 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

insufficient enrollment

Listed as NCT01235273, this PHASE2 trial focuses on Chronic Heart Failure and remains suspended. Sponsored by Federico II University, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE2
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE2
Jan 2017 — Jun 2018 [monthly]

Suspended PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Federico II University

Data source: Federico II University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Napoli, Italy